Pharmaceutical Firms

India's pharmaceutical industry should treat the proposed US tariffs on imported generic medicines as a wake-up call to reduce dependence on a single export market, diversify globally and accelerate innovation while ensuring uninterrupted access to affordable medicines, industry leaders and healthcare experts said. US President Donald Trump has announced a phased tariff framework under which imported generic medicines will continue to attract zero tariffs until August 1, 2028, before facing a 100 per cent tariff for one year and a 200 per cent tariff from August 1, 2029. The proposal, aimed at encouraging drug manufacturing in the US, has triggered a debate within India's pharmaceutical sector over its long-term implications. Nikhil K Masurkar, CEO, ENTOD Pharmaceuticals, described the proposed tariffs as an opportunity for long-term strategic transformation, rather than merely a trade challenge. "The finer details of the proposed US tariffs on generic drugs are still unclear, but

Divi's Laboratories MD Murali K Divi topped India's pharma executive pay chart in FY26 with ₹100.26 crore, driven almost entirely by profit-linked commission

Improved market access and zero tariffs under the India-UK trade agreement are expected to lift Indian pharmaceutical exports to over $980 million in FY27

Drugmaker says it will supply 6-7 million pens in the last two quarters of FY27 and restart production by November after resolving the API-related quality issue

Industry says amendments reduce procedural burden while tightening documentation and record-keeping norms for drug manufacturers under the pricing order

Draft amendments propose a 12-month minimum residual shelf life for imported drugs and an acknowledgement-based mechanism for importing medicines for research

The joint venture will invest over $20 million in a pharmaceutical manufacturing facility in Sri Lanka to boost local drug production and reduce reliance on imports

The drug pricing regulator has directed manufacturers to regularly furnish production and sales data for scheduled formulations to strengthen monitoring of essential medicines

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

Brokerage says India should focus on specialty medicines and incremental innovation rather than copying Big Pharma's new-drug discovery model

Clears way for higher rates for Cisplatin and Carboplatin amid supply crunch

India plans a new support scheme for bulk drugs focused on R&D and capacity creation, while ruling out a broad medicine price hike despite rising input costs

Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.

The Central Asian nation is offering tax breaks, infrastructure support and regulatory incentives as it seeks to become a pharmaceutical manufacturing hub for the CIS region

Cost pressures, inventory strains likely to hit margins by 3-5%

Spirulina can, indeed, prove a boon for a country like India where malnutrition, especially protein deficiency (anaemia), is rampant

Pharma major Venus Remedies Limited on Saturday said it has received marketing authorisation from the Saudi Food and Drug Authority (SFDA) for speciality oncology therapy -- Plerixafor. Plerixafor is a hematopoietic stem cell mobiliser used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant, the company said in a statement. This is the first marketing authorisation the company secured for Plerixafor anywhere in the world, it added. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and Venus Medicine Research Centre CEO, said, "This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in". "Plerixafor sits squarely in the kind of therapy class we are building our

Parexel says India is evolving into a strategic innovation and clinical research hub as global pharmaceutical firms shift high-value functions and decision-making roles

Traditional pharmacists protest as online pharmacy firms dominate India's drug retail market, outpacing brick-and-mortar players in growth and funding

CDSCO flags one batch of a liver drug as spurious and identifies 169 drugs and formulations as not of standard quality during April surveillance